(Q43040590)

English

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy

scientific article published on 24 August 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy (English)

1 reference

Europe PubMed Central

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

author name string

Shigeru Yutani

1

1 reference

Europe PubMed Central

12 November 2017

Akira Yamada

2

1 reference

Europe PubMed Central

12 November 2017

Kazumi Yoshida

3

1 reference

Europe PubMed Central

12 November 2017

Yukari Takao

4

1 reference

Europe PubMed Central

12 November 2017

Mayumi Tamura

5

1 reference

Europe PubMed Central

12 November 2017

Nobukazu Komatsu

6

1 reference

Europe PubMed Central

12 November 2017

Tatsuya Ide

7

1 reference

Europe PubMed Central

12 November 2017

Masatoshi Tanaka

8

1 reference

Europe PubMed Central

12 November 2017

Michio Sata

9

1 reference

Europe PubMed Central

12 November 2017

Kyogo Itoh

10

1 reference

Europe PubMed Central

12 November 2017

language of work or name

0 references

publication date

24 August 2007

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

25

1 reference

Europe PubMed Central

12 November 2017

42

1 reference

Europe PubMed Central

12 November 2017

7429-7435

1 reference

Europe PubMed Central

12 November 2017

Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Hepatitis C virus and the immune system: a concise review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Analysis of the CD8-positive T cell response in Japanese patients with chronic hepatitis C using HLA-A*2402 peptide tetramers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Identification of new immunogenic peptides in conserved regions of hepatitis C virus (HCV) 1b with the potentiality to generate cytotoxic T lymphocytes in HCV1b(+) HLA-A24(+) patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Identification of hepatitis C virus 1b-derived peptides recognized by both cellular and humoral immune systems in HCV1b(+) HLA-A24(+) patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Identification of hepatitis C virus (HCV) 2a-derived epitope peptides having the capacity to induce cytotoxic T lymphocytes in human leukocyte antigen-A24+ and HCV2a-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Cellular immune responses against hepatitis C virus: the evidence base 2002

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.08.005

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.08.005

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43040590&oldid=1978318097"